Clinuvel Pharmaceuticals Limited revenue by segment CUVL
Annual
Quarterly
Clinuvel Pharmaceuticals Limited splits its revenue into 2 lines in its filings. The largest line in fiscal 2026, which ended Jun 30, 2026 was Commercial Sales Of Goods at $57.9 million, 90% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
|---|---|
| Revenue |
64
|
| Commercial Sales Of Goods |
58
share 90.0%
|
| Sales Under Special Access Reimbursement Programs |
6
share 10.0%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- American Depositary Receipts (SIC 8880)
- Listed as
- CUVL (Nasdaq), CLVLF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Melbourne, Victoria
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1290877
- Former names
- EpiTan LTD (until Mar 20, 2006)
Other American Depositary Receipts companies
- Kongsberg Gruppen ASA/ADR KBGGY
- Sumitomo Electric Industries LTD/ADR/ SMTOY
- MTN Group LTD/ADR MTNOY
- Daiwa Securities Group Inc. DSEEY
- Yara International ASA YARIY
- Weir Group PLC/ADR WEGRY
- Pandora A/S / ADR PNDRY
- Vibra Energia S.A./ADR VBREY
Source: SEC EDGAR filings. This is company-reported data, not investment advice.